Esperion Therapeutics Inc (ESPR)
1.68
+0.04
(+2.44%)
USD |
NASDAQ |
Sep 27, 16:00
1.67
-0.01
(-0.60%)
After-Hours: 20:00
Esperion Therapeutics SG&A Expense (Annual): 142.52M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 142.52M |
| December 31, 2022 | 109.08M |
| December 31, 2021 | 184.98M |
| December 31, 2020 | 199.62M |
| December 31, 2019 | 65.85M |
| December 31, 2018 | 33.10M |
| December 31, 2017 | 21.38M |
| December 31, 2016 | 18.28M |
| December 31, 2015 | 20.24M |
| Date | Value |
|---|---|
| December 31, 2014 | 10.92M |
| December 31, 2013 | 6.745M |
| December 31, 2012 | 2.206M |
| December 31, 2011 | 2.357M |
| December 31, 2002 | 5.955M |
| December 31, 2001 | 5.023M |
| December 31, 2000 | 2.949M |
| December 31, 1999 | 2.518M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
65.85M
Minimum
2019
199.62M
Maximum
2020
140.41M
Average
142.52M
Median
2023
SG&A Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.06M |
| Nektar Therapeutics | 77.42M |
| Alaunos Therapeutics Inc | 12.22M |
| Oragenics Inc | 5.452M |
| Cocrystal Pharma Inc | 5.99M |